Katherine Ruffner
Seagen Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Katherine Ruffner as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01925612 · Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)Seagen Inc. · terminated · Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:14 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol · 20121,021 citationsRCR 26.5
- 569 citationsRCR 15.4
- 121 citationsRCR 2.6
- Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.Bone Marrow Transplant · 200537 citationsRCR 1.0